Carl L. G. Hansen - 22 Feb 2023 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Tryn Stimart, attorney-in-fact
Issuer symbol: ABCL
Transactions as of: 22 Feb 2023
Net transactions value: +$151,538
Form type: 4
Filing time: 23 Feb 2023, 15:33:24 UTC
Previous filing: 05 Dec 2022
Next filing: 30 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Options Exercise	$151,538	+56,125	+12%	$2.70	505,125	22 Feb 2023	Direct
holding	ABCL	Common Shares						55,859,493	22 Feb 2023	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share option (right to buy)	Options Exercise	$0	-56,125	-0.85%	$0.000000	6,557,566	22 Feb 2023	Common Shares	56,125	$2.70	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the reporting person.
F2	The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.